Sana Biotech’s islet cell remedy reveals promise in diabetes; shares surge 150% postmarket

Shares of Sana Biotechnology surged 150% on Tuesday postmarket after preliminary outcomes from a novel medical examine which will have important implications for the therapy of sort 1 diabetes.

Performed in collaboration with Uppsala College Hospital, the examine examined the corporate’s engineered islet cell remedy, UP421, in a affected person with sort 1 diabetes, with out the usage of immunosuppressive medicine.

The preliminary findings, noticed 4 weeks post-transplantation, point out that the transplanted pancreatic beta cells are surviving and functioning, as evidenced by detectable ranges of C-peptide, a marker of insulin manufacturing.

Notably, the examine reported no hostile issues of safety, and the MRI scans confirmed the continued presence of the transplanted cells, suggesting that they’ve efficiently evaded the physique’s immune response.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.